We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

AGILENT

Agilent provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling... read more Featured Products: More products

Download Mobile App




Genetic Cause Found for Rare Aggressive Ovarian Cancer

By LabMedica International staff writers
Posted on 09 Apr 2014
Print article
Image: Histopathology of small cell carcinoma of the ovary, hypercalcemic type; the tumor cells are arranged in small nests (Photo courtesy of Dr. Dharam Ramnani).
Image: Histopathology of small cell carcinoma of the ovary, hypercalcemic type; the tumor cells are arranged in small nests (Photo courtesy of Dr. Dharam Ramnani).
The genetic cause of a rare type of ovarian cancer known as small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), that most often strikes girls and young women has been revealed.

This type of cancer, SCCHOT, usually is not diagnosed until it is in its advanced stages and it does not respond to standard chemotherapy, and 65% of patients die within two years. It can affect girls as young as 14 months, and women as old as 58 years, with a mean age of only 24 years old.

An international team led by the Translational Genomics Research Institute (TGen; Phoenix, AZ, USA) analyzed the genetic etiology of SCCOHT by performing next-generation sequencing on a series of tumors and germline samples from 12 SCCOHT cases. This included nine tumors with four matched germline samples and three additional germline samples, and on the SCCOHT cell line BIN-67. DNA from tumor and blood specimens was analyzed using whole-genome sequencing and whole-exome sequencing.

Genomic DNA from each sample was fragmented to a target size of 300 to 350 base pairs (bp). After ligation, samples were run on a gel to separate products and the products were quantified using the High-Sensitivity DNA chip on an Agilent 2100 Bioanalyzer (Santa Clara, CA, USA). A tissue microarray (TMA) representing nine SCCOHT cases was fabricated at TGen for the study. Protein blot analysis was performed on whole cell extracts.

The scientists identified frequent germline and somatic gene SWItch/Sucrose NonFermentable (SWI/SNF) Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily A, Member 4 (SMARCA4) mutations and SMARCA4 protein loss in SCCOHT. The loss of SMARCA4 protein expression is extremely specific to SCCOHT and can facilitate the differential diagnosis of SCCOHT.

Jeffrey Trent, PhD, President and Research Director of TGen, and the study's senior author, said, “This is a thoroughly remarkable study. Many genetic anomalies can be like a one-lane road to cancer; difficult to negotiate. But these findings indicate a genetic superhighway that leads right to this highly aggressive disease. The correlation between mutations in SMARCA4 and the development of SCCOHT is simply unmistakable.” The study was published on March 23, 2014, in the journal Nature Genetics.

Related Links:

Translational Genomics Research Institute
Agilent


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.